NAMSW (STOCKS)
NewAmsterdam Pharma Company N.V. Warrant
—
Change: —
Prev close: —
Company Information
- Exchange
- XNAS
- Sector
- —
- Industry
- —
- CEO
- —
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- —
- Employees
- 77
- P/E (TTM)
- —
- P/B (TTM)
- —
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $22.57M |
| Benefits Costs and Expenses | $235.30M |
| Costs And Expenses | $235.30M |
| Operating Expenses | $237.74M |
| Selling, General, and Administrative Expenses | $102.65M |
| Depreciation and Amortization | $502.00K |
| Research and Development | $135.09M |
| Operating Income/Loss | -$215.18M |
| Income/Loss From Continuing Operations After Tax | -$212.73M |
| Income/Loss From Continuing Operations Before Tax | -$212.73M |
| Net Income/Loss | -$212.73M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$212.73M |
| Net Income/Loss Available To Common Stockholders, Basic | -$212.73M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.79 |
| Diluted Earnings Per Share | -$1.79 |
| Basic Average Shares | 359,792,563 |
| Diluted Average Shares | 359,792,563 |
| Assets | $732.64M |
| Current Assets | $658.04M |
| Noncurrent Assets | $74.60M |
| Fixed Assets | $379.00K |
| Non-current Prepaid Expenses | $2.59M |
| Other Non-current Assets | $71.64M |
| Liabilities | $67.42M |
| Current Liabilities | $67.42M |
| Accounts Payable | $8.09M |
| Other Current Liabilities | $59.33M |
| Noncurrent Liabilities | $0.00 |
| Equity | $665.22M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $665.22M |
| Liabilities And Equity | $732.64M |
| Net Cash Flow From Operating Activities | -$141.92M |
| Net Cash Flow From Operating Activities, Continuing | -$141.92M |
| Net Cash Flow From Investing Activities | -$189.28M |
| Net Cash Flow From Investing Activities, Continuing | -$189.28M |
| Net Cash Flow From Financing Activities | $34.07M |
| Net Cash Flow From Financing Activities, Continuing | $34.07M |
| Net Cash Flow | -$297.13M |
| Net Cash Flow, Continuing | -$297.13M |
| Comprehensive Income/Loss | -$212.95M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$212.95M |
| Other Comprehensive Income/Loss | -$89.58M |